Judge: Most Claims Can Proceed in Remicade Antitrust Claims

Drug Industry Daily
A A
A federal judge ruled Johnson & Johnson must face the majority of antitrust claims relating to its immunosuppressant Remicade (infliximab).

To View This Article:

Login

Subscribe To Drug Industry Daily